News | August 08, 2024
JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
Expect the international business including CDMO business to pick-up in the second half of the financial year
Expect the international business including CDMO business to pick-up in the second half of the financial year
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
Move to increase affordability and accessibility for heart failure patients across the country
This product is based on Osmotic Controlled Release Oral Delivery System technology
Subscribe To Our Newsletter & Stay Updated
